PBRM1 and neoplasm: Yet, PBRM1 mutations seem to be associated with poor patient outcome in these tumours (Pawlowski et al., 2013), suggesting that PBRM1 may modulate the probability of RCC cells acquiring metastatic traits at a later stage of tumour progression.